Bronchiolitis Obliterans Syndrome × Lymphoid × Clear all A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Phase 1/2 Completed
24 enrolled 67 charts
REACH 5
Phase 2 Completed
46 enrolled 21 charts
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Phase 2 Recruiting
51 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Recruiting
36 enrolled
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Phase 1 Withdrawn
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Phase 2 Completed
19 enrolled
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
27 enrolled
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Completed
95 enrolled 13 charts
Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
Recruiting
50 enrolled
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Phase 1/2 Completed
96 enrolled 13 charts
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Phase 1 Completed
24 enrolled
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Phase 1/2 Completed
260 enrolled 33 charts
Phase I Study of Milatuzumab for Graft Versus Host Disease
Phase 1 Terminated
12 enrolled
RESONATEâ„¢
Phase 3 Completed
391 enrolled 14 charts
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Phase 2 Completed
271 enrolled 32 charts
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Phase 3 Completed
266 enrolled 58 charts
ProT4
Phase 2 Unknown
114 enrolled
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
666 enrolled 110 charts
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
1,101 enrolled 46 charts
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Phase 2 Completed
15 enrolled 10 charts
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
6 enrolled
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Terminated
2,867 enrolled 77 charts
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
Phase 2 Terminated
11 enrolled 4 charts
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Completed
22 enrolled
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Phase 1 Completed
48 enrolled 27 charts
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Phase 2/3 Withdrawn
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase 2 Completed
65 enrolled 8 charts
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Phase 3 Completed
95 enrolled 37 charts
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
21 enrolled
ZicBol
Phase 4 Completed
26 enrolled
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
901 enrolled 56 charts
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
86 enrolled 15 charts
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Phase 1 Completed
7 enrolled
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Phase 1/2 Completed
25 enrolled
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Phase 1 Completed
50 enrolled
CRC005
Phase 2 Unknown
31 enrolled